The foundation behind Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, will invest €80 million ($93 million) ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Glucagon-like peptide-1 (GLP-1) agonists — weight loss medications widely used for type 2 diabetes and obesity — have been found to unexpectedly reduce alcohol consumption as a secondary benefit.

Terry Smith slammed two of Denmark’s largest life sciences companies — Novo Nordisk A/S and Coloplast A/S — after they ...

May 12, 2025 – Turns out, two really is better than one – at least when it comes to weight loss drugs. In the first head-to-head trial of its kind, people with obesity who took tirzepatide ...

The retrospective analysis included 2,694 patients (mean age 46.6 years; 78.0% female) enrolled in the program. The mean body weight was 100.5 kg and BMI was 34. 3 kg/m 2. Average weight loss at week ...

Recent research from Coventry University casts doubt on cold plunges as a weight loss method, suggesting they may increase ...

“The waist circumference difference mirrors the weight-loss results [−15.7 cm and −20 cm in semaglutide and tirzepatide, respectively],” he said, pointing out that, “The 5.4 cm greater ...

With respect to weight loss, more participants treated with tirzepatide had reductions in body weight of at least 10%, 15%, 20%, and 25%. More than 80% of those who received tirzepatide lost 10% of ...